Paul Tudor Jones Inhibrx, Inc. Transaction History

Tudor Investment Corp Et Al

  • $15.5 Billion
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$14.5 - $38.0 $48,299 - $126,578
-3,331 Reduced 15.34%
18,379 $698,000
Q3 2023

Nov 15, 2023
BUY
$15.75 - $26.31 $341,932 - $571,190
21,710 New
21,710 $398,000
Q3 2022

Nov 14, 2022
BUY
$11.58 - $24.73 $16,987 - $36,278
1,467 Added 7.77%
20,358 $365,000
Q2 2022

Aug 15, 2022
BUY
$8.52 - $25.26 $25,057 - $74,289
2,941 Added 18.44%
18,891 $214,000
Q1 2022

May 16, 2022
BUY
$19.89 - $43.18 $317,245 - $688,721
15,950 New
15,950 $355,000

Others Institutions Holding INBX

# of Institutions
132
Shares Held
35.5M
Call Options Held
64.8K
Put Options Held
91.3K
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email